SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin is gaining traction, with the community emphasizing its deflationary nature and multi-chain functionality across $SOL, $ETH, $CRO, and $BASE. Community members highlight its organic growth and strong cult following as key differentiators in the meme coin space. The potential for staking opportunities may also be contributing to the increased interest.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype is trending due to community excitement around the Hyperliquid platform and recent developments, including new staking tiers and growing transaction volume. Traders are discussing its potential for significant growth, with some comparing it to other successful DEXs. The community is closely watching price movements and key resistance levels, anticipating a breakout to new all-time highs.

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

Recall Crypto is trending due to recent initial coin offering, leading to high volume and increased attention from the community. Some traders are discussing its potential, while others are wary of a potential rug pull. The coin is also being mentioned alongside other trending tickers like $HONK, $PUMP, and $SOL.

Towns

Towns Crypto is trending as the community discusses its potential, recent price action, and possible listing on additional exchanges. Speculation around supply management and comparisons to other tokens like AVNT and BROKE are also circulating. The conversation highlights both bullish sentiment and concerns about potential dumps associated with new listings.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other Hong Kong-based stocks. Community members are pointing to the company's regained NASDAQ compliance and a substantial contract exceeding its market capitalization as key catalysts, fueling speculation about a significant move.

Monero

Monero (XMR) is gaining attention as discussions highlight its utility as a privacy coin and its potential to outperform Bitcoin. Community members are actively discussing its unique features and real-world applications, particularly in light of increasing regulatory scrutiny and the need for anonymous transactions. Some users believe XMR represents the original vision of crypto and see significant long-term growth potential.

What is HOGE? HOGE, formerly known as Hoge.Finance or Hogecoin, describes itself as a community-driven DeFi auto-staking ERC-20 token with a capped and deflationary supply. HOGE was fair-launched on February 7, 2021 with no tokens allocated to the team. Initial HOGE supply was 1,000,000,000,000 with half (500 billion) permanently burned at launch.  Deflationary Cryptocurrency A 2% tax is levied on every HOGE transaction that takes place. 1% of that tax is sent to the burn wallet and permanently removed from the supply. The other 1% is redistributed to all wallets holding HOGE outside of exchanges.  HOGE launched with the intention of simply being a deflationary “Doge but DeFi”. However, a team of HOGE founders with a larger vision stewarded the project toward a more philanthropic and utilitarian roadmap.  HOGE is one of the first DeFi memecoins to successfully complete a Certik audit. No critical, major, or medium findings were found. As of this writing the skynet security score is 90. https://www.certik.org/projects/hogefinance  HOGE has begun minting NFT's for holders as well as sponsoring eSports and Rally Racing Trucks.  In May a Swiss verein non-profit DAO hybrid was created to enact community approved actions for the token also to sign contracts and business agreements going forward with Centralized Exchange’s. HOGE has implemented a non-profit partnership initiative including a Twitter campaign called #HogeSavesTheAnimals through which the community nominates charitable causes for HOGE to support. Under this and related initiatives HOGE has raised over $20,000 for animals. The HOGE team looks to it’s HogeGameLabs to explore dApp games development later in 2021.  Articles about HOGE https://coinpedia.org/price-analysis/hoge-finance-and-meme-price-analysis/ https://www.prweb.com/releases/who_let_the_crypto_dogs_out_hoge_the_king_of_defi_made_easy/prweb17885931.htm https://jessejrogers.medium.com/can-hoge-become-heir-to-doge-496079b3c624 https://marketrealist.com/p/where-can-i-buy-hoge-crypto/

Hoge Finance

Hoge Finance is trending as community members discuss its deflationary properties and potential listing on major exchanges. Some are highlighting its recent price action and comparing it to other meme coins, while others debate the token's utility and long-term prospects. The launch on Solana is also fueling the conversation.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending amidst mixed sentiment, with some community members expressing frustration with the coin's performance and others highlighting recent partnerships and potential catalysts like a Cronos ETF. A recurring theme involves comparing $CRO's performance to that of Binance's $BNB, as well as discussing a token called $CAW(Crow with knife). Some users mention the potential impact of Trump's involvement in the crypto space.

Agnico Eagle Mines Ltd. engages in the exploration and production of gold. It operates through the following segments: Northern Business, Southern Business, and Exploration. The Northern Business segment comprises of LaRonde mine, LaRonde Zone 5 mine, Lapa mine, Goldex mine, Meadowbank mine including the Amaruq deposit, Canadian Malartic joint operation, Meliadine project and Kittila mine. The Southern Business segment consists of Pinos Altos mine, Creston Mascota mine, and La India mine. The Exploration segment represents the exploration offices in the United States, Europe, Canada, and Latin America. The company was founded by Paul Penna in 1957 and is headquartered in Toronto, Canada.

Agnico Eagle Mines Ltd

Agnico Eagle Mines ($AEM) is trending as gold prices surge, driving interest in mining stocks; the community is discussing its strong cash flow and potential for further gains, with analysts adjusting price targets upwards. Strategic equity investments, like the one in Fuerte Metals, signal confidence in future resource growth.  Some traders are noting overbought conditions, while others see $AEM as undervalued compared to its peers.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is trending amid discussions of accumulation and potential breakouts, with interest piqued by accumulation noted, tightening ranges, and rare earth export bans which could allow giants like RIO to pivot profitably. Community members are actively discussing long-term call options and potential price movements, while analysts are weighing in on production and guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Equity

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer Trinity Capital Inc. Provides $130 Million in...

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced">granted</a> Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate CAN-2409 for the treatment of a certain kind of prostate cancer.CAN-2409 is being studied for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and was previously granted FDA Fast Track designation for the same indication.RMAT designations are intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.Candel’s lead candidate was granted the designation based on positive data from a late-stage trial evaluating the efficacy and safety of the investigational drug plus a prodrug, together with external beam radiation therapy, in newly diagnosed, localized, intermediate-to-high-risk prostate cancer.Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application (BLA) seeking permission to commercialize. The company is looking to submit the application by the end of 2026.RMAT designations offer the company access to mechanisms designed to fast-track BLA review and approval.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_10_27_02_AM_png_786b86992f.webp" alt="CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits " width="628" height="63"><figcaption>CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user opined that the shares are suitable for holding in the mid- to long-term.<stembedurl>https://stocktwits.com/Bowlofpasta/message/616040223</stembedurl>According to data from Koyfin, all three analysts covering CADL rate it a ‘Buy.’ The stock has an average price target of $21.67, implying an upside of over 200% from its current value.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> is down by about 33% this year and by about 30% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/macys-q1-earnings-tops-estimates/ch0okCjRbsh">Macy’s Q1 Earnings Top Estimates, But Company Cuts 2025 Guidance Over Tariff Concerns, Weaker Consumer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy

Best Momentum Stocks to Buy for May 19th

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's  What You Should Know

Shares of Candel Therapeutics, Inc. (CADL) surged nearly 10% on Tuesday afternoon after the company reported upbeat first-quarter (Q1) earnings.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results">reported</a> diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024, and surpassing an estimated loss of $0.35 per share, as per Finchat data.It said the rise in net income was primarily related to the change in the fair value of the company’s warrant liability.While research and development expenses narrowed year-on-year in the quarter, general and administrative expenses rose.The biopharmaceutical company ended the first quarter with cash and cash equivalents of $92.2 million compared to $102.7 million as of Dec. 31, 2024. Candel expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.CEO Paul-Peter Tak said that the company’s primary focus for 2025 remains working toward submitting an application to the U.S. Food and Drug Administration (FDA) for the commercialisation of its investigational immunotherapy candidate and lead asset CAN-2409 for the treatment of prostate cancer. The submission is expected in the fourth quarter of 2026.“We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer,” he said.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel rose within the ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_41_07_PM_png_6a3877db5b.webp" alt="CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CADL/sentiment">CADL stock</a> is down by about 39% this year and 46% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-google-uber-stocks-rally-after-committing-to-invest-80-b-in-600b-us-saudi-deal/chi8AJjRbZN">AMD, Google, Uber Stocks Rally After Committing To Invest $80B As Part Of US-Saudi $600B Trade Pact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CADL News

CADLCandel Therapeutics Inc